Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 46.29% | 35.83% | 35.30% | 23.60% | 3.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 179.87% | 164.38% | 94.55% | 36.15% | -1.67% |
| Operating Income | -179.87% | -164.38% | -94.55% | -36.15% | 1.67% |
| Income Before Tax | -222.81% | -175.01% | -56.75% | -4.09% | 24.87% |
| Income Tax Expenses | 138.03% | 198.94% | 367.38% | 443.87% | 283.25% |
| Earnings from Continuing Operations | -222.52% | -175.06% | -57.11% | -4.41% | 24.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -49.18% | -71.39% | -71.81% | -63.51% | -58.73% |
| Net Income | -256.99% | -230.31% | -76.82% | -18.21% | 15.86% |
| EBIT | -179.87% | -164.38% | -94.55% | -36.15% | 1.67% |
| EBITDA | -180.21% | -163.06% | -93.25% | -34.94% | 2.77% |
| EPS Basic | -206.97% | -147.85% | -19.67% | 23.13% | 41.78% |
| Normalized Basic EPS | -231.54% | -185.79% | -28.90% | 16.13% | 36.70% |
| EPS Diluted | -206.97% | -147.85% | -19.67% | 23.13% | 41.78% |
| Normalized Diluted EPS | -231.54% | -185.79% | -28.90% | 16.13% | 36.70% |
| Average Basic Shares Outstanding | 14.69% | 28.17% | 41.78% | 50.71% | 46.49% |
| Average Diluted Shares Outstanding | 14.69% | 28.17% | 41.78% | 50.71% | 46.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |